BSE-listed Caplin Point Laboratories, headquartered in Chennai, has signed a license and distribution agreement with Cycle Pharmaceuticals Limited, based out of Cambridge, UK.
Under this agreement, Caplin Point will develop and manufacture identified liquid injectable products and Cycle Pharmaceuticals Limited will hold the ANDA and commercialize it in USA.
Caplin Point Laboratories' Chairman, Mr. C C Paarthipan indicated that the agreement has been signed for a single product for the US market. Caplin Point has already received milestone payment for the product and the company has commenced a second product development cum dossier preparation.
In another licensing agreement, Caplin Point Laboratories has entered into an agreement with Fresenius Kabi USA, LLC, a Delaware-based Limited Liability Company. Fresenius Kabi is claimed to be one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
Under the agreement, Caplin Point will be responsible for developing and manufacturing two parenteral drugs and Fresenius Kabi will hold the ANDAs and will also commercialize them in the US. This is a product specific agreement for the United States of America.
Caplin Point has received milestone payments for both the products and the product development cum dossier preparation have also commenced.